OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study

SpringerPlus

Table 2 Baseline demographics and characteristics

	OnabotulinumtoxinA 155 U (n = 132)
Mean age, years	43.2 ± 13.5 (18–76)
Female, % (n)	81.8 (108)
Diagnosis of chronic migraine, years	7.6 ± 4.3 (0.5–10)
Mean years since onset of chronic migraine	10.2 ± 4.8 (1–40)
Headache days	22.3 ± 4.1
Migraine days	21.4 ± 4.3
Pain medication intake days	20.8 ± 4.5
HIT-6 score	68.9 ± 4.3
Patients with severe HIT-6 score, % (n)	93.9 (124)

Data are presented as mean ± standard deviation; HIT headache impact test, HIT-6 Scores of 36–49 indicate little or no impact; 50–55, some impact; 56–59, substantial impact; ≥60, severe impact
Baseline data refers to the previous month before starting OnabotulinumtoxinA